L-740,093, a new antagonist of the CCK-B receptor, potentiates the antinociceptive effect of morphine: Electrophysiological and behavioural studies

Neuropeptides

Volumn 30, Issue 2, 1996, Pages 203-206

  Xu, X J ^a   Hoffmann, O ^a,b   Wiesenfeld Hallin, Z ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b Sabbatsberg Hospital   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (3 AZABICYCLO[3.2.2]NON 3 YL) 2,3 DIHYDRO 1 METHYL 2 OXO 1H 1,4 BENZODIAZEPIN 3 YL] 3 (3 METHYLPHENYL)UREA; CHOLECYSTOKININ B RECEPTOR ANTAGONIST; MORPHINE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ANTINOCICEPTION; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DECEREBRATION; DOSE RESPONSE; DRUG PENETRATION; DRUG POTENTIATION; INTRAVENOUS DRUG ADMINISTRATION; MALE; NEUROMODULATION; NONHUMAN; PAIN ASSESSMENT; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALIA;

EID: 0029982334     PISSN: 01434179     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4179(96)90088-8     Document Type: Article

References (18)

1. Baber NS, Dourish CT, Hill DR. The role of CCK, caerulein, and CCK antagonists in nociception. Pain 1989; 39: 307-328.
2. Wiesenfeld-Hallin Z, Xu X-J. The role of cholecystokinin type B receptor in nociception studied with peptide agonist and antagonist. In: Coon PM, ed. Methods in neuroscience, vol. 11. Receptors in neural systems. New York: Academic press, 1992: 148-169.
3. Dourish CT, O'Neill MF, Coughlan J, Kitchener SJ, Hawley D, Iversen SD. The selective CCK-B receptor antagonist L-365, 260 enhances morphine analgesia and prevents morphine tolerance in the rat. Eur J Pharmacol 1990; 176: 35-44.
4. Wiesenfeld-Hallin Z, Xu X-J, Horwell DC, Hughes J, Hökfelt T. PD134308, a selective antagonist of cholecystokinin type B receptor, enhances the analgesic effect of morphine and synergistically interacts with intrathecal galanin to depress spinal nociceptive reflexes. Proc Natl Acad Sci USA 1990; 87: 7105-7109.
5. Zhou Y, Sun YH, Zhang ZW, Han JS. Increased release of immunoreactive cholecystokinin octapeptide by morphine and potentiation of μ-opioid analgesia by CCKB receptor antagonist L365,260 in rat spinal cord. Eur J Pharmacol 1993; 234: 147-154.
6. Noble F, Blommaert A, Foumiezaluski MC, Roques BP. A selective CCK-B receptor antagonist potentiates mu-, but not delta-opioid receptor-mediated antinociception in the formalin test. Eur J Pharmacol 1995; 273:145-151
7. Stanfa L, Dickenson A H, Xu X-J, Wiesenfeld-Hallin Z. Cholecystokinin and morphine analgesia: variations on a theme. Trends Pharmacol Sci 1994; 15: 65-67
8. Xu X-J, Hao J-X, Sciger A, Hughes J, Hökfelt T, Wiesenfeld-Hallin Z. Chronic pain-related behaviours in spinally injured rats: evidence for functional alterations of the endogenous cholecystokinin and opioid systems. Pain 1994; 56: 271-278.
9. Xu X-J, Puke MJC, Verge VMK, Wiesenfeld-Hallin Z, Hughes J, Hökfelt T. Up-regulation of cholecystokinin in primary sensory neurons is associated with morphine insensitivity in experimental neuropathic pain. Neurosci Lett 1993; 152: 129-132.
10. Arner S, Meyerson BA. Lack of analgesic effect of opioids on neuropathic and idiopathic forms of pain. Pain 1988; 43: 287-297.
11. Bock MG, DiPardo RM, Evans BE et al. Benzodiazepine gastrin and brain cholecystokinin receptor ligands: L-365, 260. J Med Chem 1989; 32: 13-16.
12. Hughes J, Boden P, Costall B et al. Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 1990; 87: 6728-6732.
13. Howbert JJ, Lobb KL, Brown RF et al. A novel series of non-peptide CCK and gastrin antagonists: medicinal chemistry and electrophysiological demonstration of antagonism. In: Dourish CT, Cooper SJ, Iversen SD, Iversen LL, eds. Multiple cholecystokinin receptors in the CNS. Oxford: Oxford University Press, 1992: 28-37
14. Showell GA, Bourrain S, Neduvelil JG et al. High affinity and potent, water-soluable 5-amino-1, 4-benzodiazepine CCKB/gastrin receptor antagonists containing a cationic solubilizing group. J Med Chem 1994; 37: 719-721.
15. Patel S, Smith AJ, Chapman KL et al. Biological properties of benzodiazepine amidine derivative: identification of L-740,093, one of the most potent in vitro and in vivo CCK-B/gastrin receptor antagonists known. Mol Pharmacol 1994; 46: 943-948.
16. Wall PD, Woolf CJ. Muscle but not cutaneous C-afferent input produces prolonged increases in the excitability of the flexion reflex in the rat. J Physiol 1984; 356: 443-458.
17. Xu X-J, Wiesenfeld-Hallin Z, Hughes J, Horwell DC, Hökfelt T. CI988, a selective antagonist of cholecystokinin B receptors, prevents morphine tolerance in the rat. Br J Pharmacol 1992; 105: 591-596.
18. Chen H, Downs DA. Opioid thermal analgesia in mice produced by systemic administration of A CCK-B antagonist. Abst Soc Neurosci 1991; 17:1012.